<DOC>
	<DOCNO>NCT01127646</DOCNO>
	<brief_summary>The main purpose study help understand effect child adolescents stable treatment atomoxetine osmotic-release oral system ( OROS ) methylphenidate attention-deficit/hyperactivity disorder ( ADHD ) take medication maximum 6 day 28-day study treatment period .</brief_summary>
	<brief_title>A Study Attention Deficit Hyperactivity Disorder Children Adolescents</brief_title>
	<detailed_description>The present study design assess effect miss dos daily medication ( off-days ) . On off-days patient take placebo ( sugar pill ) . Over 4 week actual study 6 random off-day study medicine neither caregiver , patient study doctor know day miss day . To cover aspect patient ' life notably school time , aside investigator 's assessment , evaluation also perform daily basis involve day-to-day life : parent , teacher ( school day ) patient , use electronic diary .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients must meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) diagnostic criterion attentiondeficit/hyperactivity disorder ( ADHD ) , confirm screen administer Kiddie Schedule Affective Disorders Schizophrenia School Aged ChildrenPresent Lifetime Version . Patients must AttentionDeficit/Hyperactivity Disorder Rating Scale IV Parent Version : Investigator Administered Scored , total score less equal 20 screen baseline . Patients must Clinical Global ImpressionAttentionDeficit/Hyperactivity DisorderImprovement score 1 ( `` much good '' ) 2 ( `` much good '' ) screen baseline . Patients must take either atomoxetine osmoticrelease oral system methylphenidate treatment ADHD 3 maximum 15 month prior screen . Patients must receive dose atomoxetine osmoticrelease oral system methylphenidate monotherapy single daily dose 4 week prior screen . For female childbearing potential : Test negative pregnancy time entry base urine pregnancy test Signed informed consent document ( ICD ) Patients weigh less 20 kilogram ( kg ) 70 kg study entry Documented history bipolar disorder , history psychosis pervasive development disorder . Patients history seizure disorder patient take anticonvulsant treatment seizure control . Patients serious suicidal risk . History severe allergy one class medication multiple adverse drug reaction . Patients acute unstable medical condition include cardiovascular disease hypertension . Patients take excluded concomitant medication likely begin structure psychotherapy ADHD . Patients currently enrol , discontinue within last 30 day clinical trial . Sexually active female use medically acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>